GETI.B

209.6

+1.11%↑

CAMX

608

0%↓

BIOAB

318.2

-0.31%↓

EKTA.B

55.6

-0.27%↓

VITR

137.7

-0.22%↓

GETI.B

209.6

+1.11%↑

CAMX

608

0%↓

BIOAB

318.2

-0.31%↓

EKTA.B

55.6

-0.27%↓

VITR

137.7

-0.22%↓

GETI.B

209.6

+1.11%↑

CAMX

608

0%↓

BIOAB

318.2

-0.31%↓

EKTA.B

55.6

-0.27%↓

VITR

137.7

-0.22%↓

GETI.B

209.6

+1.11%↑

CAMX

608

0%↓

BIOAB

318.2

-0.31%↓

EKTA.B

55.6

-0.27%↓

VITR

137.7

-0.22%↓

GETI.B

209.6

+1.11%↑

CAMX

608

0%↓

BIOAB

318.2

-0.31%↓

EKTA.B

55.6

-0.27%↓

VITR

137.7

-0.22%↓

Home・Akciju saraksts・Vivesto AB

Vivesto AB

Atvērts

0.22

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

0.22

Max

0.22

Galvenie mērījumi
By Trading Economics
Ienākumi	2.3M -7.2M
EPS	-0.013
Darbinieki	4

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-8.3M 70M
Iepriekšējā atvēršanas cena	0.22
Iepriekšējā slēgšanas cena	0.22

Vivesto AB Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 11. dec. 23:58 UTC

Iegādes, apvienošanās, pārņemšana

Destination XL to Merge With Oaktree-Backed Fullbeauty Brands -- Update

2025. g. 11. dec. 23:56 UTC

Peļņas

Costco Logs Higher Sales, Eyes Expansion to Fuel Membership Growth -- Update

2025. g. 11. dec. 23:03 UTC

Iegādes, apvienošanās, pārņemšana

FTC Sues to Block Henkel's $725 Million Acquisition of Liquid Nails From PE Firm

2025. g. 11. dec. 22:06 UTC

Iegādes, apvienošanās, pārņemšana

Scentre to Sell $456 Million Westfield Chermside Mall Stake to Dexus-Managed Fund

2025. g. 11. dec. 21:50 UTC

Peļņas

Costco Same-Store Sales, Membership Fees Rose in 1Q

2025. g. 11. dec. 23:45 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2025. g. 11. dec. 23:44 UTC

Tirgus saruna

Nikkei May Rise After U.S. Stock Indexes Hit Record Highs -- Market Talk

2025. g. 11. dec. 23:37 UTC

Tirgus saruna

Gold Steady, Underpinned by Dollar's Weakness -- Market Talk

2025. g. 11. dec. 23:31 UTC

Peļņas

Broadcom Beats Revenue and Profit Forecasts as AI Chip Sales Climb -- Update

2025. g. 11. dec. 22:48 UTC

Iegādes, apvienošanās, pārņemšana

FTC Sues to Block Henkel's $725M Acquisition of Liquid Nails From PE Firm

2025. g. 11. dec. 22:35 UTC

Peļņas

Costco Sold 4.5 Million Pies Ahead of Thanksgiving. Despite Earnings Beat, the Stock Fails to Gain Traction. -- Barrons.com

2025. g. 11. dec. 22:30 UTC

Peļņas

Broadcom Beats Earnings. The Stock Wavers After Customer Updates. -- Barrons.com

2025. g. 11. dec. 22:09 UTC

Iegādes, apvienošanās, pārņemšana

FTC Alleges Henkel Deal Would Combine Two Biggest Brands of Construction Adhesives Sold at Stores Like Home Depot, Leading to Higher Prices

2025. g. 11. dec. 22:06 UTC

Iegādes, apvienošanās, pārņemšana

FTC Sues to Block Henkel From Buying Loctite Competitor Liquid Nails

2025. g. 11. dec. 22:05 UTC

Peļņas

Broadcom Beats Revenue and Profit Forecasts as AI Chip Sales Climb -- Update

2025. g. 11. dec. 21:51 UTC

Iegādes, apvienošanās, pārņemšana

Scentre to Sell $456M Westfield Chermside Mall Stake to Dexus-Managed Fund

2025. g. 11. dec. 21:50 UTC

Tirgus saruna

Auto & Transport Roundup: Market Talk

2025. g. 11. dec. 21:39 UTC

Peļņas

Broadcom Beats Earnings. The Stock Rises. -- Barrons.com

2025. g. 11. dec. 21:39 UTC

Peļņas

Broadcom Reports $18 Billion in Revenue as AI Chip Sales Climb -- WSJ

2025. g. 11. dec. 21:38 UTC

Peļņas

Costco Tops Earnings Estimates but Stock Fails to Gain Traction -- Barrons.com

2025. g. 11. dec. 21:37 UTC

Peļņas

These Stocks Moved the Most Today: Oracle, Nvidia, Broadcom, Planet Labs, Visa, Ciena, Gemini Space Station, and More -- Barrons.com

2025. g. 11. dec. 21:37 UTC

Tirgus saruna

Broadcom Sees AI Revenue Doubling -- Market Talk

2025. g. 11. dec. 21:34 UTC

Iegādes, apvienošanās, pārņemšana

Scentre Will Temporarily Invest A$50M in the New Dexus Fund

2025. g. 11. dec. 21:29 UTC

Iegādes, apvienošanās, pārņemšana

Dexus Aiming for Long-Term Holding of A$50M in Fund

2025. g. 11. dec. 21:28 UTC

Tirgus saruna

BLS Publishing Calendar Delays Now Pushing Economic Data Into February -- Market Talk

2025. g. 11. dec. 21:28 UTC

Iegādes, apvienošanās, pārņemšana

Dexus Expects to Introduce Additional Third-Party Equity in FY26

2025. g. 11. dec. 21:28 UTC

Iegādes, apvienošanās, pārņemšana

Dexus: Third Party Investors to Contribute Remainder

2025. g. 11. dec. 21:27 UTC

Iegādes, apvienošanās, pārņemšana

Dexus to Put Initial A$170M into New Dexus Strategic Investment Trust

2025. g. 11. dec. 21:26 UTC

Iegādes, apvienošanās, pārņemšana

Scentre: Dexus Wholesale Shopping Centre Fund Already Holds 25% Stake

2025. g. 11. dec. 21:25 UTC

Iegādes, apvienošanās, pārņemšana

Scentre: Purchase Price Represents Book Value, 5% Value Cap Rate

Salīdzinājums

Cenas izmaiņa

Vivesto AB Prognoze

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Vivesto AB

Vivesto AB develops, produces, markets, and sells drugs in the field of human and veterinary oncology in Sweden. Its lead product is Apealea (paclitaxel micellar) for the treatment of ovarian cancer. The company's products portfolio includes Docetaxel micellar, a patented formulation that combines cytotoxin docetaxel with XR-17, which is in Phase 1b clinical trial for the treatment of prostate cancer; and Cantrixil to treat ovarian cancer. its animal health product portfolio includes Paccal Vet, a formulation of paclitaxel with its XR-17 encapsulation technology for the treatment of canine mastocytoma; and Doxophos Vet, a patented formulation of doxorubicin to treat lymphoma. The company was formerly known as Oasmia Pharmaceutical AB (publ) and changed its name to Vivesto AB in March 2022. Vivesto AB was incorporated in 1988 and is headquartered in Solna, Sweden.